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A B S T R A C T
Background: Postprandial hyperlipidemia and hyperinsulinemia have been thought to play an important
role in the development of atherosclerosis. Diabetes mellitus (DM) has an impact on lipid metabolism,
however, little is known about the relationship between the postprandial lipid and glucose metabolism
in normoglycemic patients with coronary artery disease (CAD).
Methods: To compare the postprandial lipid and glucose metabolism in normoglycemic patients with
and without CAD, a total of 36 normoglycemic patients: 19 patients with stable CAD (CAD group, age
60.2  11.3 years) and 17 patients without CAD (Non-CAD group, age 60.4  9.6 years) were loaded with a
high-fat and high-glucose test meal, and the changes in serum level of the lipid and glucose parameters were
monitored before and 0, 2, 4, and 6 h later.
Results: In the Non-CAD group, postprandial serum levels of triglycerides (TG) and remnant-like particle
cholesterol increased signiﬁcantly and reached peak levels at the 4th hour and decreased signiﬁcantly at
the 6th hour of observation, whereas those levels in CAD group kept rising during 6 h of observation.
Although there was no signiﬁcant difference in the area under the curves (AUCs) for the postprandial
plasma glucose levels between CAD and Non-CAD group, the AUCs for the postprandial plasma insulin
and C-peptide levels were signiﬁcantly higher in the CAD group than in the Non-CAD group. The AUCs for
postprandial TG levels showed good correlation with those for postprandial plasma insulin and C-
peptide levels (insulin: r = 0.455, p < 0.005; C-peptide: r = 0.462, p < 0.05).
Conclusions: These ﬁndings suggest that postprandial hyperlipidemia and hyperinsulinemia may have a
close relationship in CAD patients without DM and might play an important role in the development of
atherosclerosis even before the onset of diabetes.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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A coronary plaque rupture followed by thrombus formation is
well known as a major cause of acute myocardial infarction (MI)
[1], and it is also widely accepted that high serum levels of low-
density lipoprotein cholesterol (LDL-C) play a crucial role in* Corresponding author at: Department of Cardiology, Iwate Prefectural Central
Hospital, 1-4-1 Ueda, Morioka 020-0066, Japan. Tel.: +81 19 653 1151;
fax: +81 19 653 2528.
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0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsthe initiation and progression of coronary arterial plaque. Despite
currently available optimal LDL-C lowering therapies, a worri-
some number of clinical events still occur [2,3]. It has been
reported that not only LDL-C but also triglycerides (TG), TG-rich
lipoproteins, and their partially hydrolyzed products such as
chylomicron remnants that carry dietary derived fats may play
a role in progression or vulnerability of coronary arterial plaque
[4–6]. Because of the accumulation of excess TG-rich lipoproteins
and their hydrolyzed products in non-fasting state, it has been
suggested that postprandial hyperlipidemia is closely related to
the development of the plaque and the following cardiac events.
However, the characteristics of postprandial hyperlipidemia in reserved.
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studied. In the present study, we examined the postprandial lipid
proﬁles in patients with CAD when compared with patients
without CAD.
It has been shown that patients with abnormalities of glucose
metabolism revealed hypertriglyceridemia in both fasting and
non-fasting state [4,6], and the suggestion is made that there will
be a close relationship between postprandial hyperlipidemia and
insulin resistance. In the present study, we focused on CAD
patients without diabetes mellitus (DM) for excluding the effect of
DM on the postprandial lipid metabolism, and also examined
whether postprandial hyperlipidemia was linked with postpran-
dial hyperinsulinemia in CAD patients when compared with
patients without CAD.
Methods
Study subjects
A total of 36 male normoglycemic patients: 19 patients with
stable CAD (CAD group, mean age 60.2  11.3 years) and 17 patients
without CAD matched by age (Non-CAD group, mean age
60.4  9.6 years) who fulﬁlled the following exclusion criteria, were
loaded with a high-fat and high-glucose test meal at Iwate Prefectural
Central Hospital from January to June 2013: (1) gastrointestinal
disease limiting drug absorption or partial ileal bypass; (2) major
surgery within 6 months prior to enrollment or concomitant
inﬂammatory disease or malignant tumors; (3) congestive heart
failure or active liver disease or hepatic dysfunction deﬁned as alanine
aminotransferase or aspartate aminotransferase greater than normal
range; (4) concurrent therapy with long-term immunosuppressants;
(5) familial hypercholesterolemia; (6) taking lipid-lowering medica-
tions without statins (ezetimibe, cholestyramine, niacin, or ﬁbrates)
and/or eicosapentaenoic acid or docosahexaenoic acid therapy.
Before starting the present study, we conducted a pilot study to
estimate the normal response in serum lipid levels and glucose
metabolism. After obtaining informed consent from 10 healthy
young male volunteers (mean age 25.6  1.2 years) who were
resident physicians at Iwate Prefectural Central Hospital, the pilot
study was conducted.
This study was conducted according to the principles expressed
in the Declaration of Helsinki. Written informed consent was
obtained from the subjects and the study design was approved by
the ethics committee of the Iwate Prefectural Central Hospital.
Deﬁnitions
Patients with stable CAD (CAD group) were deﬁned as cardiac
ischemic patients who had a history of MI, coronary artery bypass,
percutaneous coronary intervention (PCI) with or without stent-
ing, or previous angiographically proved stenotic lesion 75% in a
major epicardial coronary artery. They were also diagnosed as
being in a stable condition when chest pain was brought on by
exertion, resolved under nitrate-therapy, and not changed in its
characteristics (frequency, severity, duration, time of appearance,
and precipitating factors) for the previous 60 days [7].
Patients without CAD (Non-CAD group) were deﬁned as being
non-cardiac ischemic patients matched for age and sex who had no
previous MI, no previous PCI, and angiographically proven normal
coronary arteries.
Normoglycemic patients were deﬁned as patients without
dysglycemia which was indicated by the presence of either
prediabetes or type 2 DM. Diagnosis of type 2 DM was made
according to American Diabetes Association criteria of a fasting
plasma glucose (FPG) level of 126 mg/dL, hemoglobin A1c
(HbA1c) (JDS) 6.5%, or current use of hypoglycemic agents orinsulin. Prediabetes was indicated by a FPG level of 100–125 mg/dL
or a HbA1c level of 5.7–6.4% without type 2 DM [8].
Study design
For fat loading, patients were given an oral high-fat and high-
glucose meal for breakfast after overnight fasting for at least 12 h
(named as cake sa´le test). This cake sa´le consisted of high-fat and
high-glucose (1003 kcal; protein, 28.6 g; lipids, 62.4 g; carbohy-
drate, 80.7 g; cholesterol, 320.5 mg) and its ingredients were
similar to those of an American fast-food meal (Big Mac
Cheeseburger1 with French fries, Coca-Cola1) which was one of
the most popular foods in the world [9]. Patients were requested to
eat this high-fat and high-glucose meal (cake sa´le) in 30 min. Blood
samples were collected during the fasting state just before the cake
sa´le test and 0, 2, 4, and 6 h after the cake sa´le load.
Before starting the present study, we conducted a pilot study to
estimate the normal response in serum lipid levels and glucose
metabolism. After obtaining informed consent from 10 healthy
young male volunteers who were resident physicians at our
hospital, the pilot study was conducted.
Measurements of lipid and glucose parameters
The following lipid parameters were measured before and 2, 4,
and 6 h after the cake sa´le test: serum total cholesterol (TC), TG,
LDL-C, high-density lipoprotein cholesterol (HDL-C), remnant-like
particle cholesterol (RLP-C), malondialdehyde-modiﬁed LDL
(MDA-LDL), apolipoprotein A (Apo A), and apolipoprotein B (Apo
B). Serum levels of TC and TG were determined by enzymatic
methods, serum LDL-C and HDL-C levels by a direct method, serum
MDA-LDL levels by a sandwich enzyme-linked immunosorbent
assay method, serum Apo A and Apo B levels by an immuno-
turbidity method, and serum RLP-C levels by the immunoafﬁnity
isolation method, respectively, at a contract laboratory (SRL Co.,
Ltd., Tokyo, Japan). Serum LDL-C levels were determined by direct
measurement and not by calculation with the Friedewald formula,
since the postprandial TG levels were predicted to be more than
400 mg/dL.
Plasma glucose and insulin, and C-peptide levels were also
measured for the assessment of glucose metabolism before and
after a meal load. Plasma insulin levels were determined by a
chemiluminescent enzyme immunoassay method, plasma C-
peptide levels by a radioimmunoassay method, and HbA1c levels
by a high-performance liquid chromatography method, respec-
tively, at the laboratory of our hospital.
The areas under the curve (AUCs) of these parameters were also
calculated by the trapezoidal method and were compared to
estimate the response of each group in the cake sa´le test. All
samples were treated in accordance with the Helsinki Declaration.
Indices of insulin resistance
In the present study, the following insulin resistance param-
eters were measured: (1) the homeostasis model assessment of
insulin resistance (HOMA-IR), (2) the Matsuda-DeFronzo index
(ISI-M), (3) fasting insulin or C-peptide level, (4) insulin or C-
peptide level at 2 h after the cake sa´le test, and (5) TG/HDL-C level.
The HOMA-IR was calculated as [fasting plasma glucose (mg/
dL)  fasting plasma insulin (mIU/mL)/405] [10]. The ISI-M was
calculated as based on the results of the cake sa´le test: ISI-
M = 10,000/[G0  I0  Gmean  Imean]1/2, where G and I represents
plasma glucose [mg/dL] and insulin [mU/L] concentrations,
respectively, and ‘0’ and ‘mean’ indicates fasting value and mean
value during the cake sa´le test, respectively [11,12]. All fasting
values were obtained before the cake sa´le test.
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Results are expressed as the mean  SD. Differences between
variables measured before and after the cake sa´le test were assessed
using the paired Student’s t-test. Differences between groups were
assessed using the unpaired Student’s t-test for continuous variables
and chi square tests for categorical variables. Correlation between the
two parameters was determined by simple linear regression analysis.
A value of p < 0.05 was considered signiﬁcant. All statistical analyses
were performed with SPSS version 14.0 (SPSS Inc., Chicago, IL, USA).
Results
Characteristics in study patients
Table 1 shows the characteristics in all of the patients: young
healthy volunteers, CAD, and Non-CAD groups. In the Non-CAD
group, 10 patients were admitted to our hospital for radio-
frequency catheter ablation and 7 patients were admitted for
pacemaker implantation. As shown in Table 1, some patients in the
healthy volunteer and CAD groups received no measurement of
some lipid and glucose markers.
There were no signiﬁcant differences between CAD and Non-
CAD groups in age and body size. However, there were several
signiﬁcant differences between the CAD and Non-CAD groups. All
patients in the CAD group had received statins, whereas the
number of patients who used them was only 3 of 17 patients in the
Non-CAD group (100% vs. 18%, p < 0.001). Serum TC, LDL-C, and
MDA-LDL levels at baseline were signiﬁcantly lower in the CAD
group than in the Non-CAD group. Patients in the CAD group also
showed lower serum levels of HDL-C and Apo A compared to those
in the Non-CAD group. The prevalence of hypertension and usageTable 1
Baseline clinical characteristics in patients.
Young volunteers
(n = 10)
CAD
(n
Age (years) 25.6  1.2 60
Weight (kg) 63.7  6.8 65
Height (cm) 174.3  5.3 164
BMI (kg/m2) 21.0  2.0 23
25 (n) (%) 0 (0) 5
Lipid markers
Total cholesterol (mg/dL) 170.2  18.5 160
Triglyceride (mg/dL) 66.0  20.3 119
LDL cholesterol (mg/dL) 100.1  20.0 92
HDL cholesterol (mg/dL) 61.1  7.7 49
RLP cholesterol (mg/dL) 2.9  0.8 3
MDA LDL (U/L) 103.1  30.4 110
Apolipoprotein AI (mg/dL) 131.6  14.2 129
Apolipoprotein B (mg/dL) 71.0 13.9 82
Use of statin (n) (%) 0 (0) 19
Use of other lipid lowering medications (n) (%) 0 (0) 0
Blood pressure (mmHg)
Systolic 119.5  8.3 116
Diastolic 78.2  7.4 71
Hypertension (n) (%) 0 (0) 11
Use of antihypertensive medications (n) (%) 0 (0) 11
Glucose markers
Fasting plasma glucose (mg/dL) 90.3  7.8 86
HbA1c (%) 5.2  0.3 5
Fasting plasma insulin (mIU/mL) 4.6  1.6 6
Fasting plasma C-peptide (ng/mL) 1.2  0.3 1
Current or ex-smokers (n) (%) 0 (0) 15
Data are mean  SD or n (%). CAD, coronary artery disease; BMI, body mass index; LDL, low
malondialdehyde-modiﬁed; HbA1c, hemoglobin A1c.of antihypertensive agents was higher in the CAD group than in the
Non-CAD group, and blood pressure level at baseline was
signiﬁcantly lower in the CAD group than in the Non-CAD group
(p = 0.039 in systole; p = 0.010 in diastole). The prevalence of
current or past smoking was higher in the CAD group than in the
Non-CAD group (79% vs. 29%, p = 0.024). HbA1c level was similar
between CAD and Non-CAD groups (5.4  0.2 vs. 5.4  0.2,
p = 0.856), and there was also no difference in plasma levels of
fasting glucose and insulin between those two groups (glucose,
p = 0.567; insulin, p = 0.192).
Postprandial lipid metabolism in CAD vs. Non-CAD Group
The change in lipid parameters in the cake sa´le test is
summarized in Table 2. The serum TG level in the Non-CAD group
was 84.6  38.2 mg/dL at baseline and increased postprandially to
144.1  47.3 mg/dL at the 2nd hour (vs. baseline value, p < 0.001),
178.8  73.5 mg/dL at the 4th hour (vs. baseline value, p < 0.001),
and then decreased signiﬁcantly to 113.6  32.5 mg/dL at the 6th
hour of observation (vs. value at the 4th hour, p < 0.005) (Fig. 1A).
This response in the Non-CAD group was similar to that in young
volunteers. At 6 h after the load, the recovery ratio to the baseline
value from the peak was 67.0  23.7% (from 178.8  73.5 mg/dL to
113.6  32.5 mg/dL). On the other hand, the serum TG level in the
CAD group was signiﬁcantly higher than that in the Non-CAD group at
baseline (119.1  54.5 mg/dL vs. 84.6  38.2 mg/dL, p = 0.034), and it
kept rising during 6 h after the load (212.9  79.7 mg/dL at the 4th
hour vs. 209.4  97.6 mg/dL at the 6th hour, p = 0.681). In the AUC of
serum TG, there was no signiﬁcant difference between the Non-CAD
group and young volunteers (p = 0.707), however the AUC of serum
TG in the CAD group was signiﬁcantly greater than that in the Non-
CAD group or young volunteers (p = 0.025, p = 0.035, respectively) group
 = 19)
Non-CAD group
(n = 17)
Unmeasured
data (n; young
volunteers/CAD
group/Non-CAD
group)
p-value CAD vs.
Non-CAD group
.2  11.3 60.4  9.6 0/0/0 0.814
.0  12.5 61.1  11.8 0/0/0 0.861
.9  5.7 162.8  9.4 0/0/0 0.627
.8  4.2 22.8  2.7 0/0/0 0.913
 (26) 4 (24) 0/0/0 0.052
.9  19.6 187.4  27.8 0/0/0 0.007
.1  54.5 84.6  38.2 0/0/0 0.104
.1  16.9 111.0  16.5 0/0/0 0.003
.9  11.9 63.4  14.3 0/0/0 0.005
.4  2.2 3.5  2.4 2/0/0 0.853
.3  31.2 112.0  41.0 2/0/0 0.348
.3  26.9 147.1  27.7 2/5/0 0.038
.1  13.7 84.5  9.6 2/0/0 0.337
 (100) 3 (18) 0/0/0 <0.001
 (0) 0 (0) 0/0/0 –
.6  15.5 128.2  16.8 0/0/0 0.039
.0  10.2 81.3  12.6 0/0/0 0.010
 (58) 6 (35) 0/0/0 0.331
 (58) 6 (35) 0/0/0 0.331
.6  5.5 86.0  6.5 0/0/0 0.567
.4  0.2 5.4  0.2 0/0/0 0.856
.5  4.3 4.3  1.9 3/5/0 0.192
.7  0.6 1.2  0.3 3/1/0 0.017
 (79) 5 (29) 0/0/0 0.024
-density lipoprotein; HDL, high-density lipoprotein; RLP, remnant lipoprotein; MDA,
Table 2
Change in lipid and glucose markers after the high-fat and high-glucose test meal.
Before After
0 h 2 h 4 h 6 h
Total cholesterol (mg/dL)
Young volunteers (n = 10) 170.2  18.5 169.3  19.3 171.5  19.7 171.8  18.7 176.5  25.3
CAD group (n = 19) 160.9  19.6 165.1  20.1 159.4  18.7 158.3  17.4 159.8  17.6
Non-CAD group (n = 17) 187.4  27.8 188.6  24.4 183.9  27.9 183.1  25.1 186.2  25.9
Triglyceride (mg/dL)
Young volunteers (n = 10) 66.0  20.3 68.5  23.0 158.5  63.0y 157.3  69.2y 103.5  47.1*
CAD group (n = 19) 119.1  54.5 119.1  48.5 166.1  47.1y 212.9  79.7y 209.4  97.6y
Non-CAD group (n = 17) 84.6  38.2 83.1  32.7 144.1  47.3y 178.8  73.5y 113.6  32.5*
LDL cholesterol (mg/dL)
Young volunteers (n = 10) 100.1  20.0 99.1  19.3 97.7  20.1§ 97.2  19.1* 104.0  23.5
CAD group (n = 19) 92.1  16.7 94.8  18.3§ 90.4  16.5 88.3  16.3§ 89.5  15.3
Non-CAD group (n = 17) 111.0  16.5 111.8  14.9 106.1  16.6y 104.4  15.3y 109.1  15.6
HDL cholesterol (mg/dL)
Young volunteers (n = 10) 61.1  7.7 63.1  13.3 62.1  11.7 61.2  11.9 64.3  10.9
CAD group (n = 19) 49.9  11.9 51.4  10.8§ 48.9  9.8 47.7  9.1§ 48.3  10.3
Non-CAD group (n = 17) 63.4  14.3 64.1  12.9 61.8  15.0* 60.8  14.0y 63.8  14.5
RLP cholesterol (mg/dL)
Young volunteers (n = 8) 2.9  0.8 3.0  1.0 6.9  2.6* 7.2  3.2* 4.4  1.8§
CAD group (n = 19) 3.4  2.2 3.5  1.9 5.3  1.8y 7.1  2.9y 6.9  4.0y
Non-CAD group (n = 17) 3.5  2.4 3.3  1.7 5.8  1.8y 6.9  2.2y 4.2  0.7
MDA LDL (U/L)
Young volunteers (n = 8) 103.1  30.4 104.0  24.7 97.6  21.3 94.8  21.0 99.5  25.8
CAD group (n = 19) 110.3  31.2 121.3  45.4§ 113.9  42.6 105.8  31.3 107.1  37.8
Non-CAD group (n = 17) 112.0  41.0 110.1  40.9 99.6  36.6* 100.3  34.9z 103.7  34.8
Apolipoprotein AI (mg/dL)
Young volunteers (n = 8) 131.6  14.2 128.4  13.5* 133.0  13.4 130.7  13.3 132.7  12.6
CAD group (n = 14) 129.3  26.9 134.2  25.9z 128.9  21.8 126.8  21.0 127.6  23.2
Non-CAD group (n = 17) 147.1  27.7 148.5  23.8 143.2  28.2z 142.8  26.2y 144.9  27.3
Apolipoprotein B (mg/dL)
Young volunteers (n = 8) 71.0  13.9 69.5  13.0§ 71.4  14.7 70.5  12.8 72.6  15.9
CAD group (n = 19) 82.1  13.7 85.1  14.8z 82.1  14.5 81.5  15.0 81.1  13.8
Non-CAD group (n = 17) 84.5  9.6 85.5  8.3 82.0  10.0y 82.0  8.9y 83.8  9.8
Fasting plasma glucose (mg/dL)
Young volunteers (n = 10) 90.3  7.8 109.4  18.4* 94.7  13.9 90.4  6.8 88.8  4.7
CAD group (n = 19) 86.6  5.5 109.3  15.1y 96.6  14.4z 92.9  10.1 94.2  5.9
Non-CAD group (n = 17) 86.0  6.5 107.9  12.0y 93.1  12.0* 85.6  8.0 92.2  4.3
Fasting plasma insulin (mIU/mL)
Young volunteers (n = 7) 4.6  1.6 21.0  13.3§ 14.1  8.6§ 7.3  3.1 3.6  1.4
CAD group (n = 14) 6.5  4.3 25.0  14.1y 26.1  18.5y 16.0  14.0z 10.5  13.2
Non-CAD group (n = 17) 4.3  1.9 18.4  8.9y 15.7  6.0y 6.4  2.5* 3.3  1.7
Fasting plasma C-peptide (ng/mL)
Young volunteers (n = 7) 1.2  0.3 2.9  1.4z 2.9  1.0* 2.1  0.8* 1.2  0.4
CAD group (n = 18) 1.7  0.6 3.5  1.3y 5.6  1.9y 3.8  2.0y 2.8  2.1§
Non-CAD group (n = 17) 1.2  0.3 2.5  1.0y 4.2  1.0y 2.3  0.5y 1.3  0.4
Data are mean  SD. CAD, coronary artery disease; LDL, low-density lipoprotein; HDL, high-density lipoprotein; RLP, remnant lipoprotein; MDA, malondialdehyde-modiﬁed.
* p < 0.005 vs. value before the test meal.
y p < 0.001 vs. value before the test meal.
z p < 0.01 vs. value before the test meal.
§ p < 0.05 vs. value before the test meal.
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a baseline value of <100 mg/dL. Although there was no signiﬁcant
difference at baseline between the CAD group (n = 10) and Non-CAD
group (n = 12) (74.3  14.0 mg/dL vs. 65.3  13.6 mg/dL, p = 0.069),
the responses in CAD and Non-CAD groups were similar to those as
shown in Fig. 1A. As shown in Fig. 1D, the serum RLP-C level kept
rising during 6 h after the load (7.1  2.9 mg/dL at the 4th hour vs.
6.9  4.0 mg/dL at the 6th hour, p = 0.770) in the CAD group, whereas
that in the Non-CAD group and volunteers increased postprandially
during 4 h after the load, and then decreased signiﬁcantly at the 6th
hour of observation (Non-CAD group, 6.9  2.2 mg/dL at the 4th hour
vs. 4.2  0.7 mg/dL at the 6th hour, p < 0.001; young volunteers,
7.2  3.2 mg/dL at the 4th hour vs. 4.4  1.8 mg/dL at the 6th hour,
p = 0.007).
Fig. 2 shows the relationship between serum TG and RLP-C
level or AUC of serum TG and RLP-C in the cake sa´le test. In each
group, there existed a good correlation between serum TG and
RLP-C.Other lipid parameters (TC, LDL-C, HDL-C, MDA-LDL, Apo A, and
Apo B) showed no signiﬁcant changes in serum levels before and
after the cake sa´le test (Table 2).
Postprandial glucose metabolism in CAD vs. Non-CAD group
The change in glucose parameters in the cake sa´le test is
summarized in Table 2. Plasma glucose level in each group
increased signiﬁcantly just after the cake sa´le test (CAD group:
from 86.6  5.5 mg/dL to 109.3  15.1 mg/dL, p < 0.001; Non-CAD
group: from 86.0  6.5 mg/dL to 107.9  12.0 mg/dL, p < 0.001;
young volunteers: 90.3  7.8 mg/dL to 109.4  18.4 mg/dL,
p < 0.005), and it recovered to the baseline level at the 4th hour
of observation (Fig. 3A). These responses were not signiﬁcantly
different among each group, and the AUCs of plasma glucose were
also not signiﬁcantly different between CAD and Non-CAD groups
(p = 0.103) (Fig. 3B). Plasma insulin and C-peptide levels recovered
to the baseline level at 6 h later in the Non-CAD group and young
Fig. 1. Postprandial changes in serum TG (A and C) and RLP-C (D) levels after the fat loading test in CAD (solid circles), Non-CAD (solid square), and young healthy volunteer
(solid triangle) groups, and comparison of AUCs for postprandial serum TG level during the test in three groups (B). Data are expressed as mean  SD. #p = ns, yp < 0.001,
*p < 0.005, zp < 0.01 comparing with the value at the 4th hour after the load in the same group. TG, triglycerides; RLP-C, remnant-like particle cholesterol; CAD, coronary artery
disease; AUC, area under the curve.
Fig. 2. Relationship between serum TG and RLP-C level (left panels), and that between AUC for serum TG and RLP-C (right panels). TG, triglycerides; RLP-C, remnant-like
particle cholesterol; CAD, coronary artery disease; AUC, area under the curve.
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Fig. 3. Postprandial changes in plasma glucose (A) level after the fat loading test in CAD (solid circles), Non-CAD (solid square) and young healthy volunteer (solid triangle)
groups, and comparison of AUCs for postprandial plasma glucose level during the test in three groups (B). Data are expressed as mean  SD. #p = ns, when comparing CAD and
Non-CAD groups. CAD, coronary artery disease; AUC, area under the curve.
A. Nakamura et al. / Journal of Cardiology 66 (2015) 435–444440volunteers, however, those in the CAD group were signiﬁcantly
higher during 6 h after the load when compared with the baseline
value (Fig. 4A and C).
Insulin resistance markers between CAD vs. Non-CAD group
The data on insulin resistance markers in each group are
summarized in Table 3. Plasma insulin levels at the baseline or the
2nd hour after the load were not signiﬁcantly different between CAD
and Non-CAD groups (p = 0.092, p = 0.062, respectively), however,
the AUCs of plasma insulin during the test were signiﬁcantly greater
in the CAD group than the Non-CAD group (p = 0.020) (Fig. 4B).
Plasma C-peptide levels at the baseline or the 2nd hour of
observation were signiﬁcantly higher in the CAD group than the
Non-CAD group (p = 0.004, p = 0.008, respectively), and also the AUC
of plasma C-peptide during the test was signiﬁcantly greater in the
CAD group than the Non-CAD group (p = 0.001) (Fig. 4D).
HOMA-IR showed no signiﬁcant difference between CAD and
Non-CAD groups (p = 0.183) (Fig. 4E), however, ISI-M in the CAD
group was signiﬁcantly smaller than in the Non-CAD group
(p = 0.020) (Fig. 4F). Between Non-CAD group and young volun-
teers, there were no signiﬁcant differences in HOMA-IR and ISI-M
(p = 0.612, p = 0.670, respectively) (Fig. 4E and F).
The TG/HDL-C ratio increased postprandially during 4 h after
the load and then decreased signiﬁcantly at the 6th hour of
observation in the Non-CAD group and young volunteers (Fig. 4G).
On the other hand, that in the CAD group kept rising during 6 h
after the load (Fig. 4H). The AUC of TG/HDL-C ratio in the CAD
group was signiﬁcantly greater than that in the Non-CAD group
(p = 0.004). Between the Non-CAD group and young volunteers,
there were no signiﬁcant difference in the AUC of TG/HDL-C ratio
(p = 0.568).
In the CAD-group, the AUC of plasma insulin or C-peptide was
signiﬁcantly correlated with that of serum TG (insulin, p < 0.001,
r = 0.455; C-peptide, p < 0.005, r = 0.462) (Fig. 5A and B), whereas
there did not exist a correlation between the AUC of serum TG and
that of plasma insulin or C-peptide in the Non-CAD-group (Fig. 5C
and D).
Discussion
The present study examined postprandial lipid and glucose
metabolism between non-diabetic patients with and without CAD.
The main ﬁndings of this study were as follows: First, non-diabetic
patients with CAD showed a prolonged delay in recovery to
baseline level of postprandial serum TG and RLP-C as compared
with those without CAD. Secondly, postprandial hyperinsulinemia
was characterized by a prolonged response in non-diabeticpatients with CAD rather than those without CAD, and insulin
resistance was higher in patients with CAD than those without
CAD. Thirdly, the magnitude of postprandial TG accumulation,
which was shown as the area under the TG curve over 6 h after the
test, might correlate with prolonged hyperinsulinemia in non-
diabetic patients with CAD.
Several epidemiological studies have demonstrated that not
only fasting but also non-fasting hyperlipidemia are an important
factor in the development of atherosclerosis and closely related to
the occurrence of cardiovascular events [13,14]. In non-fasting
state, especially postprandial state, the hyperlipidemia is charac-
terized by accumulation of excess TG-rich lipoproteins and their
partially hydrolyzed products such as chylomicron remnant (CM-
R) and very low-density lipoprotein remnant (VLDL-R) that carry
dietary derived fats may play a role in progression or vulnerability
of atherosclerosis. The westernization of life style resulted in an
increase in the prevalence of dyslipidemia in the Japanese
population [15]. For estimation of the risk for CAD, the measure-
ment of lipid parameters such as serum TG and RLP-C may be more
important in postprandial state than fasting state.
Although the different responses of serum TG or RLP-C levels
after loading test were shown between healthy subjects and
patients with type 2 DM [13], there is little information as to the
postprandial response in CAD patients without DM. This is the ﬁrst
report showing the different postprandial lipid metabolism after
loading test in patients with CAD as compared with healthy
subjects, even if they did not have DM. The Copenhagen City Heart
Study, which was a large-scale prospective and general popula-
tion-based cohort study, reported that nonfasting TG levels were
associated with risk of ischemic stroke independent of other risk
factors including DM [16]. The Women’s Health Study also showed
that the relationship between nonfasting TG levels and cardiovas-
cular events persisted after adjustment for many markers of DM,
HDL-C level, blood pressure, BMI, and high sensitivity C-reactive
protein level [6]. These previous studies and our results suggest
that higher TG levels in postprandial status are an independent risk
factor for CAD even in non-diabetic patients, and that they might
support the broad hypothesis that atherosclerosis is, at least in
part, a ‘‘postprandial phenomenon.’’
An increase in serum TG levels contributes not only to the
augmentation of RLP-C level but also to the high prevalence of
small dense LDL particles [17]. The small dense LDL-C is
considered to promote atherosclerosis via increased entry into
and retention in the arterial wall because they have a low afﬁnity
for LDL receptors [18] and susceptibility to oxidative modiﬁcation
[19,20]. Because we could not measure directly small dense LDL-C
levels in the present study, the LDL-C/Apo B ratio was estimated as
a good predictor of LDL particle size and a surrogate marker of
Fig. 4. (A–D) Postprandial changes in plasma insulin (A) and C-peptide (C) levels after the fat loading test in CAD (solid circles), Non-CAD (solid square), and young healthy
volunteer (solid triangle) groups, and comparison of AUCs for postprandial plasma insulin (B) and C-peptide (D) levels during the test in three groups. (E and F) Comparison of
HOMA-IR (E) and ISI-M (F) among CAD, Non-CAD, and young healthy volunteer groups. (G and H) Postprandial changes in TG/HDL-C ratio (G) after the fat loading test in CAD
(solid circles), Non-CAD (solid square), and young healthy volunteer (solid triangle) groups, and comparison of AUC for value of TG/HDL-C during the test in three groups (H).
Data are expressed as mean  SD. #p = ns, yp < 0.001, *p < 0.005, zp < 0.01, §p < 0.05 comparing CAD and Non-CAD group. CAD, coronary artery disease; AUC, area under the curve;
HOMA-IR, homeostasis model assessment of insulin resistance; ISI-M, Matsuda-DeFronzo index; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol.
A. Nakamura et al. / Journal of Cardiology 66 (2015) 435–444 441smaller sized LDL particle [21,22]. Interestingly, although serum
LDL-C levels in patients with CAD were controlled with statins at
less than 100 mg/dL (92  16.9 mg/dL) and they were signiﬁcantly
lower than that in patients without CAD (111.0  16.5 mg/dL,
p = 0.003) (shown in Table 1), the LDL-C/Apo B ratio was
signiﬁcantly lower in patients with CAD rather than those withoutCAD (1.13  0.08 vs. 1.31  0.06, p < 0.0001). These results were
compatible with the report by Tani et al., demonstrating that not
only the absolute serum LDL-C levels, but also the qualitative
characteristics of LDL particle (especially particle size) may be a
useful index that differs in patients treated by statin with and without
CAD [22].
Table 3
Comparison of insulin resistance markers between CAD and Non-CAD group.
Young volunteers CAD group Non-CAD group p-value CAD vs.
Non-CAD group
Fasting insulin (mU/mL) 4.6  1.6 (n = 7) 6.5  4.3 (n = 14) 4.2  1.9 (n = 17) 0.192
2-h insulin (mU/mL) 14.1  8.6 (n = 7) 26.1  18.5 (n = 14) 15.7  6.0 (n = 17) 0.062
AUC insulin (mU/mL1 6 h1) 73.8  22.4 (n = 7) 127.5  78.5 (n = 14) 71.5  17.7 (n = 17) 0.020
Fasting C-peptide (ng/mL) 1.2  0.3 (n = 7) 1.7  0.6 (n = 18) 1.2  0.3 (n = 17) 0.017
2-h C-peptide (ng/mL) 2.9  1.0 (n = 7) 5.6  1.9 (n = 18) 4.2  1.0 (n = 17) 0.008
AUC C-peptide (ng/mL1 6 h1) 15.1  4.3 (n = 8) 26.4  9.1 (n = 18) 17.7  3.3 (n = 17) 0.001
HOMA-IR 1.01  0.41 (n = 7) 1.34  1.06 (n = 14) 0.92  0.41 (n = 17) 0.183
ISI-M 1.74  0.75 (n = 7) 1.25  0.5 (n = 14) 1.89  0.92 (n = 17) 0.020
TG/HDL-C ratio 1.11  0.37 (n = 10) 2.60  1.50 (n = 19) 1.39  0.60 (n = 17) 0.003
AUC TG/HDL-C 13.8  5.6 (n = 10) 25.1  12.2 (n = 19) 15.2  5.9 (n = 17) 0.004
CAD, coronary artery disease; AUC, area under the curve; HOMA-IR, homeostasis model assessment of insulin resistance; ISI-M, Matsuda-DeFronzo insulin sensitivity
index; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol.
A. Nakamura et al. / Journal of Cardiology 66 (2015) 435–444442An increase in remnant lipoproteins such as CM-R and VLDL-R
has been also thought to be atherogenic as well as small dense
LDL-C [23]. It has been reported that remnant lipoproteins could
induce foam cell formation and proliferation of smooth muscle
cells in arterial wall [23]. In the present study, the responses of
serum RLP-C level in the cake sa´le test were fundamentally the
same as those of serum TG level in each group, and also there
existed a good correlation between serum TG and RLP-C levels.
Masuda et al. [24] reported that postprandial increase in serum TG
and RLP-C levels was mainly due to increase of CM and CM-R, but
not VLDL and VLDL-R. Namely, postprandial hyperlipidemia is
thought to be caused by the impaired postprandial metabolism
of TG-rich lipoproteins in exogenous pathway rather thanFig. 5. Correlations between the value of AUC for postprandial serum TG level and that fo
in Non-CAD group (C: insulin; D: C-peptide). AUC, area under the curve; TG, triglyceriendogeneous pathway. In patients with DM, the absorption of
cholesterol was shown to be higher in CAD patients than Non-CAD
patients [25]. It was also demonstrated that impaired cholesterol
homeostasis, reﬂected by lower synthesis markers such as
lathosterol and higher absorption markers such as campesterol,
was a highly signiﬁcant independent predictor of CAD in the
Framingham Offspring Study Cycle-6 participants including
approximately 30% of patients with DM [26]. Thus, higher
cholesterol absorption efﬁciency has been shown in CAD patients
with DM, however, there is little information on cholesterol
malabsorption in CAD patients without DM. Although we do not
have any direct data demonstrating the mechanism of postpran-
dial prolonged concentration of serum TG and RLP-C in CADr postprandial plasma insulin or C-peptide in CAD group (A: insulin; B: C-peptide) or
des; CAD, coronary artery disease.
A. Nakamura et al. / Journal of Cardiology 66 (2015) 435–444 443patients without DM, it would be interesting to investigate the
association between cholesterol absorption and the prolonged
response after the load in these patients.
It has been shown that postprandial hyperlipidemia is
associated with insulin resistance which is a well-known risk
factor for CAD, especially in patients with DM. Ai et al. reported
the postprandial prolonged concentration of serum RLP-C in DM
patients with insulin resistance by using the OFTT (Oral Fat
Tolerance Test) cream load test [27]. In insulin-resistant state, the
intestinal overproduction of CM and the increase of serum CM-R
owing to reduced activity of lipoprotein lipase have been
demonstrated from clinical studies and animal experimentations
[28,29]. In the present study, the postprandial responses of
several insulin resistance parameters were compared between
CAD and Non-CAD patients without DM after the fat load. The
postprandial increase of plasma insulin or C-peptide levels after
the load was shown to be greater in CAD patients than Non-CAD
patients without DM. And the sum of the amount of increase of
plasma insulin or C-peptide values during the test was
signiﬁcantly higher in CAD patients as compared with Non-CAD
patients without DM. Thus even with normal metabolism of
glucose, the possibility exists that CAD patients are insulin
resistant compared with Non-CAD patients, and it suggests that
patients with postprandial hyperinsulinemia may be at higher
risk of the development of atherosclerosis even before the onset of
diabetes. The fundamental mechanism of insulin resistance is not
clearly understood, however, it has been identiﬁed as increasing
the risk of CAD in a series of prospective studies in non-diabetic
individuals [30–33].
In the present study, all patients in the CAD group and 3 of
17 patients in the Non-CAD group were treated with statins.
Although there have been several reports that statins cause an
increase in insulin resistance that leads to the occurrence of type
2 DM [34], the effect of statins on insulin resistance remains
controversial to date. The euglycemic hyperinsulinemic clamp
studies have not shown consistent changes in insulin resistance
[35]. Furthermore, the meta-analysis by Baker et al. [36] revealed
that statins did not signiﬁcantly alter insulin resistance compared
to placebo. In addition, they reported different effect of statins on
insulin resistance: decrease in insulin resistance by pravastatin,
increase by simvastatin, and no change by atorvastatin or
rosuvastatin. In the present study, 5 patients and 14 patients in
CAD group had received atorvastatin and rosuvastatin, respective-
ly; one patient and two patients in the Non-CAD group had
received atorvastatin and rosuvastatin, respectively. Thus, it seems
to be a poor possibility that insulin resistance was under the
inﬂuence of statin therapy. In the clinical setting, it is not easy to
perform clinical research with data from patients receiving
nonstatin therapy, because statin therapy was recommended for
secondary prevention of CAD according to the guidelines [37]. Data
from patients without statin therapy would contribute to better
understanding of the relationship between postprandial lipid
metabolism and insulin resistance. Furthermore, the comparison
between CAD and Non-CAD patients with statin therapy might
enable us to provide more important information. Unfortunately,
the number of patients in the CAD group was small (n = 5) for
statistical analysis.
As shown in the present study, it is likely that postprandial
hyperlipidemia is closely related to postprandial hyperinsulinemia
in CAD patients without DM when compared with Non-CAD
patients. To the best of our knowledge, this is the ﬁrst report
showing the relationship between postprandial hyperlipidemia
and hyperinsulinemia in CAD and Non-CAD patients without DM.
There is clinical evidence to indicate that metformin which is an
oral antidiabetic drug in the biguanide class [38], pioglitazone
which is an agonist of peroxisome proliferator-activated receptor[39], or a-glucosidase inhibitor which inhibits the absorption of
carbohydrates in the gastrointestinal tract [40], reduce the risk of
cardiovascular events in patients with type 2 DM. The anti-
atherosclerotic effect of these drugs which reduce insulin
resistance might be produced partially via improvement of
postprandial hyperinsulinemia and/or hyperlipidemia. Although
the subjects of the present study were not diabetic patients, it
would be interesting to investigate the effects of these drugs for
postprandial lipid metabolism.
Study limitations
There are several limitations to the present study. First, it was a
study by a single-facility and limited by the small number of
patients, which might have caused a statistical bias. Nevertheless,
the results were found to be clear and statistically signiﬁcant.
Second, all subjects of the present study were male patients to
exclude the hormonal effect by estrogen on postprandial lipid
metabolism. Third, all patients in the CAD group were treated with
statins, whereas those patients in the Non-CAD group were only
18% (p = 0.0002). Because the possibility exists that the effective
inhibition of hepatic cholesterol synthesis by statins leads to the
increase of intestinal absorption of cholesterol [41], further
investigation into cholesterol absorption/synthesis markers such
as cholestanol or lathosterol [26] would provide valuable
additional information in the present study. Fourth, it has been
reported that insulin resistance coincides with lower HDL-C and
Apo A levels [42]. Smoking has also been reported as a factor for an
increase in insulin resistance [43]. In the present study, the
possibility exists that higher insulin resistance in the CAD group
was affected by these factors. As shown in Table 1, a large standard
deviation of fasting plasma insulin values in the CAD group might
suggest that the factors related to insulin resistance are not simple
but appear to be multifactorial.
Conclusions
The present study suggests that postprandial hyperlipidemia
and hyperinsulinemia may have a close relationship in CAD
patients without DM. The postprandial lipid and glucose metabo-
lism might play an important role in the development of
atherosclerosis even before the onset of diabetes.
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